The immune cell dynamics in the peripheral blood of cHL patients receiving anti-PD1 treatment

The immune cell dynamics in the peripheral blood of cHL patients receiving anti-PD1 treatment

Checkpoint blockade therapy (CBT) involving anti-PD1 antibodies represents the standard approach for cHL patients who do not respond to second-line therapy. Nonetheless, only 20% of relapsed/refractory (R/R) cHL patients treated with CBT achieve complete remission. In this study, we extensively exam...

Full description

Bibliographic Details
Main Authors: Vanessa Cristaldi, Lodovico Terzi di Bergamo, Lucrezia Patruno, Marinos Kallikourdis, Giada Andrea Cassanmagnago, Francesco Corrado, Eleonora Calabretta, Adalgisa Condoluci, Martina di Trani, Daoud Rahal, Gianluca Basso, Clelia Peano, Alex Graudenzi, Marco Antoniotti, Davide Rossi, Carmelo Carlo-Stella
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-03-01
Series:Frontiers in Oncology
Subjects:
Hodgkin (cHL)
single-cell analysis
TCR - T cell receptor
immunotherapy
refractoriness
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2025.1518107/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2025.1518107/full

Similar Items